Pittenger & Anderson Inc. Lowers Stock Position in iShares Biotechnology ETF (NASDAQ:IBB)

Pittenger & Anderson Inc. cut its holdings in shares of iShares Biotechnology ETF (NASDAQ:IBBGet Rating) by 12.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,054 shares of the financial services provider’s stock after selling 421 shares during the period. Pittenger & Anderson Inc.’s holdings in iShares Biotechnology ETF were worth $466,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Diligent Investors LLC acquired a new stake in iShares Biotechnology ETF in the fourth quarter valued at $201,000. Benjamin Edwards Inc. raised its stake in iShares Biotechnology ETF by 16.9% during the fourth quarter. Benjamin Edwards Inc. now owns 1,044 shares of the financial services provider’s stock worth $159,000 after purchasing an additional 151 shares during the period. Blue Fin Capital Inc. raised its stake in iShares Biotechnology ETF by 30.2% during the fourth quarter. Blue Fin Capital Inc. now owns 16,037 shares of the financial services provider’s stock worth $2,447,000 after purchasing an additional 3,721 shares during the period. Future Financial Wealth Managment LLC purchased a new position in shares of iShares Biotechnology ETF in the 4th quarter valued at $30,000. Finally, Fifth Third Bancorp increased its stake in iShares Biotechnology ETF by 2.4% during the 4th quarter. Fifth Third Bancorp now owns 43,033 shares of the financial services provider’s stock worth $6,568,000 after buying an additional 1,009 shares during the period. Institutional investors and hedge funds own 63.88% of the company’s stock.

Shares of NASDAQ IBB traded up $3.27 during midday trading on Thursday, hitting $109.73. The company’s stock had a trading volume of 450,242 shares, compared to its average volume of 2,898,386. The firm’s fifty day moving average price is $125.18 and its 200-day moving average price is $137.39. iShares Biotechnology ETF has a 1-year low of $106.14 and a 1-year high of $177.37.

The business also recently declared a quarterly dividend, which was paid on Wednesday, March 30th. Stockholders of record on Friday, March 25th were given a dividend of $0.118 per share. This represents a $0.47 dividend on an annualized basis and a dividend yield of 0.43%. This is a boost from iShares Biotechnology ETF’s previous quarterly dividend of $0.04. The ex-dividend date was Thursday, March 24th.

iShares Biotechnology ETF Company Profile (Get Rating)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Further Reading

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBBGet Rating).

Institutional Ownership by Quarter for iShares Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.